Boehringer, Walgreens Team Up for Obesity Trial as Weight-Loss Drug Race Heats Up

Boehringer Ingelheim is tapping consumer health chain Walgreens to conduct a large-scale Phase III clinical trial in obesity and type 2 diabetes, the companies announced on Thursday.

The strategic collaboration will make use of certain Walgreens community pharmacies as clinical trial sites, allowing patients to participate “within the familiar and accessible environment of Walgreens pharmacies,” according to the announcement. The partnership aims to optimize recruitment and make clinical trials “more accessible, inclusive and equitable.”